文献速递呼吸道感染呼吸危重症与机械通气

伊马替尼治疗重症COVID-19:一项随机双盲安慰剂对照临床试验

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.
PubMed 文献 · Lancet Respir Med · 2021-06-18

在荷兰13家医院开展的随机双盲安慰剂对照试验中,400例需补氧的COVID-19住院患者被分配至伊马替尼组或安慰剂组。主要终点(停用机械通气和补氧超过48小时的时间)两组无显著差异;

核心结论

  • 研究未达到主要终点,伊马替尼未能缩短需补氧COVID-19患者停用通气和补氧超过48小时的时间。
  • 观察到的生存获益和机械通气持续时间缩短提示伊马替尼可能带来临床获益,但需进一步研究验证。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,在荷兰13家学术和非学术教学医院进行。
  • 纳入≥18岁、RT-PCR确诊SARS-CoV-2、需补氧维持SpO2>94%的住院患者,排除严重基础肺病、心衰、近12个月活动性肿瘤治疗、血细胞减少或与伊马替尼强相互作用药物者。
  • 400例患者随机1:1分配至伊马替尼组(n=204)或安慰剂组(n=196),385例(96%)接受至少一剂药物并纳入改良意向治疗人群,中位年龄64岁(IQR 56-73)。
  • 伊马替尼口服:第0天负荷800mg,第1-9天每日400mg;主要终点为28天内停用机械通气和补氧超过48小时且存活的时间。

主要发现

  • ≥3级不良事件:伊马替尼组91/197(46%),安慰剂组82/188(44%);安全性评估未发现伊马替尼相关不良事件。

临床怎么用

  • 目前证据不支持常规使用伊马替尼缩短COVID-19患者停用通气和补氧的时间。
  • 观察到的生存和机械通气持续时间获益需进一步研究验证,暂不能作为临床推荐依据。

局限性

  • 校正基线失衡后死亡HR的95%CI包含1,生存获益证据不确切。
  • 研究未达到主要终点,次要终点结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental and early clinical data suggest that the tyrosine-kinase inhibitor imatinib reverses pulmonary capillary leak. METHODS: This randomised, double-blind, placebo-controlled, clinical trial was done at 13 academic and non-academic teaching hospitals in the Netherlands. Hospitalised patients (aged ≥18 years) with COVID-19, as confirmed by an RT-PCR test for SARS-CoV-2, requiring supplemental oxygen to maintain a peripheral oxygen saturation of greater than 94% were eligible. Patients were excluded if they had severe pre-existing pulmonary disease, had pre-existing heart failure, had undergone active treatment of a haematological or non-haematological malignancy in the previous 12 months, had cytopenia, or were receiving concomitant treatment with medication known to strongly interact with imatinib. Patients were randomly assigned (1:1) to receive either oral imatinib, given as a loading dose of 800 mg on day 0 followed by 400 mg daily on days 1-9, or placebo. Randomisation was done with a computer-based clinical data management platform with variable block sizes (containing two, four, or six patients), stratified by study site. The primary outcome was time to discontinuation of mechanical ventilation and supplemental oxygen for more than 48 consecutive hours, while being alive during a 28-day period. Secondary outcomes included safety, mortality at 28 days, and the need for invasive mechanical ventilation. All efficacy and safety analyses were done in all randomised patients who had received at least one dose of study medication (modified intention-to-treat population). This study is registered with the EU Clinical Trials Register (EudraCT 2020-001236-10). FINDINGS: Between March 31, 2020, and Jan 4, 2021, 805 patients were screened, of whom 400 were eligible and randomly assigned to the imatinib group (n=204) or the placebo group (n=196). A total of 385 (96%) patients (median age 64 years [IQR 56-73]) received at least one dose of study medication and were included in the modified intention-to-treat population. Time to discontinuation of ventilation and supplemental oxygen for more than 48 h was not significantly different between the two groups (unadjusted hazard ratio [HR] 0·95 [95% CI 0·76-1·20]). At day 28, 15 (8%) of 197 patients had died in the imatinib group compared with 27 (14%) of 188 patients in the placebo group (unadjusted HR 0·51 [0·27-0·95]). After adjusting for baseline imbalances between the two groups (sex, obesity, diabetes, and cardiovascular disease) the HR for mortality was 0·52 (95% CI 0·26-1·05). The HR for mechanical ventilation in the imatinib group compared with the placebo group was 1·07 (0·63-1·80; p=0·81). The median duration of invasive mechanical ventilation was 7 days (IQR 3-13) in the imatinib group compared with 12 days (6-20) in the placebo group (p=0·0080). 91 (46%) of 197 patients in the imatinib group and 82 (44%) of 188 patients in the placebo group had at least one grade 3 or higher adverse event. The safety evaluation revealed no imatinib-associated adverse events. INTERPRETATION: The study failed to meet its primary outcome, as imatinib did not reduce the time to discontinuation of ventilation and supplemental oxygen for more than 48 consecutive hours in patients with COVID-19 requiring supplemental oxygen. The observed effects on survival (although attenuated after adjustment for baseline imbalances) and duration of mechanical ventilation suggest that imatinib might confer clinical benefit in hospitalised patients with COVID-19, but further studies are required to validate these findings. FUNDING: Amsterdam Medical Center Foundation, Nederlandse Organisatie voor Wetenschappelijk Onderzoek/ZonMW, and the European Union Innovative Medicines Initiative 2.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Aman J, Duijvelaar E, Botros L, et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med. 2021. PMID: 34147142. doi:10.1016/S2213-2600(21)00237-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。